- Home
- CMA vs ROIV Comparison
CMA vs ROIV Comparison
Compare CMA & ROIV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | CMA | ROIV |
|---|---|---|
| Founded | 1849 | 2014 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 10.1B | 14.1B |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | CMA | ROIV |
|---|---|---|
| Price | $88.48 | $22.56 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 21 | 8 |
| Target Price | ★ $71.45 | $24.31 |
| AVG Volume (30 Days) | 1.5M | ★ 8.2M |
| Earning Date | 01-21-2026 | 02-09-2026 |
| Dividend Yield | ★ 3.22% | N/A |
| EPS Growth | ★ 30.50 | N/A |
| EPS | ★ 5.23 | N/A |
| Revenue | ★ $3,234,000,000.00 | $20,329,000.00 |
| Revenue This Year | $6.42 | N/A |
| Revenue Next Year | $3.03 | $376.94 |
| P/E Ratio | $16.88 | ★ N/A |
| Revenue Growth | ★ 2.31 | N/A |
| 52 Week Low | $48.12 | $8.73 |
| 52 Week High | $90.44 | $23.47 |
Technical Indicators
Market Signals| Indicator | CMA | ROIV |
|---|---|---|
| Relative Strength Index (RSI) | 70.94 | 61.61 |
| Support Level | $87.54 | $21.60 |
| Resistance Level | $89.16 | $23.47 |
| Average True Range (ATR) | 1.72 | 0.88 |
| MACD | 0.21 | 0.06 |
| Stochastic Oscillator | 78.55 | 69.09 |
Price Performance
Historical ComparisonAbout CMA Comerica Incorporated
With assets of around $80 billion, Comerica is primarily a relationship-based commercial bank headquartered in Dallas. In addition to Texas, Comerica's other primary geographies are California and Michigan, with locations also in Arizona and Florida and select businesses operating in several other states as well as Canada and Mexico.
About ROIV Roivant Sciences Ltd.
Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. Its drug candidate VTAMA (tapinarof) is a treatment of plaque psoriasis in adult patients and is in its commercial stage. The other drug candidates in their different stages of development are; Batoclimab, IMVT-1402, Brepocitinib, Namilumab, and others.